NCT05088356 2025-12-19Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftStanford UniversityPhase 1 Recruiting60 enrolled
NCT03017820 2025-10-08A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaMayo ClinicPhase 1 Recruiting127 enrolled
NCT01895842 2025-02-28Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer CenterPhase 1 Completed31 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01164163 2014-10-23INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseChildren's Oncology GroupPhase 1 Completed49 enrolled